Brief: Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534
15/07/2024 13:09
July 15 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL ANNOUNCES ENROLLMENT COMPLETED AND DOSING
INITIATED
FOR SIXTH DOSE COHORT OF PHASE 1/2 STUDY OF ONCT-534 FOR THE
TREATMENT OF R/R METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* ONCTERNAL THERAPEUTICS INC - INITIAL UPDATE ON ONCT-534
SAFETY
AND EFFICACY EXPECTED IN Q3 2024
Source text for Eikon: ID:nGNX4btGyt
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;